GSA Capital Partners LLP Invests $303,000 in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

GSA Capital Partners LLP acquired a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 6,249 shares of the company’s stock, valued at approximately $303,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. TD Asset Management Inc lifted its holdings in shares of Amphastar Pharmaceuticals by 67.4% during the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock worth $67,663,000 after acquiring an additional 680,976 shares during the period. Epoch Investment Partners Inc. lifted its holdings in Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after purchasing an additional 280,390 shares during the last quarter. American Century Companies Inc. lifted its holdings in Amphastar Pharmaceuticals by 19.7% during the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock valued at $29,616,000 after purchasing an additional 121,764 shares during the last quarter. Millennium Management LLC lifted its holdings in Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after purchasing an additional 338,653 shares during the last quarter. Finally, Boston Trust Walden Corp bought a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at about $26,189,000. 65.09% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the sale, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. The trade was a 7.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the sale, the director now owns 75,409 shares of the company’s stock, valued at approximately $3,504,256.23. This represents a 3.83 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 31,533 shares of company stock valued at $1,571,652. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Trading Up 2.0 %

Shares of NASDAQ AMPH opened at $45.46 on Friday. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $65.92. The company has a market cap of $2.19 billion, a PE ratio of 14.82, a P/E/G ratio of 0.87 and a beta of 0.82. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company has a 50-day moving average of $48.31 and a two-hundred day moving average of $44.42.

Analysts Set New Price Targets

AMPH has been the subject of several analyst reports. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler cut their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Finally, Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a report on Friday. They set an “equal weight” rating and a $55.00 price target for the company. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $60.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.